Stock market announcement archive

October 15, 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. Reference is made to the stock exchange announcement made by Lifecare ASA (the “Company“) on 8 October […]
Read more
August 30, 2024
Reference is made to the Q2 2024 report published by Lifecare ASA (the “Company”) on 27 August 2024. In connection with the uplisting to Euronext Oslo Børs, the Company has conducted new assessments of its financial statements and, in collaboration with its auditor, concluded to recognize the warrants issued in connection with the previously announced […]
Read more
August 27, 2024
Bergen, Norway, 27 August 2024: Today, Lifecare ASA (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q2 financial report and operational update. In the second quarter Lifecare continued to build positive momentum towards automatic production by delivering milestones on a continuous basis over a long […]
Read more
August 13, 2024
Bergen, Norway, August 13, 2024: Lifecare ASA, a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), is pleased to announce a strategic cooperation with OneTwo Analytics AB (OneTwo), a Swedish-based company specializing in data analytics of diabetes data. The strategic cooperation will provide Lifecare access to OneTwo’s portfolio of comprehensive […]
Read more
June 13, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF […]
Read more
June 13, 2024
Bergen, Norway, June 13th, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company has concluded a successful in-vitro quality test of sensor for use in longevity study. Reference is made to stock exchange notification June 10th, 2024. The internal in-vitro quality […]
Read more
June 10, 2024
Bergen, Norway, June 10th, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company have improved the read-out distance from sensor to the read-out device. Reference is made to previous communications in the Q1 reporting regarding the need to improve the read-out […]
Read more
May 8, 2024
Bergen, Norway, May 5th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q1 financial report and operational update. Lifecare Q1 report 2024 is available here Lifecare has been delivering milestones on a continuous basis over a long period. The company has […]
Read more
April 26, 2024
Bergen, Norway 26 April 2024: Hannibal Invest AS, a company closely associated with Hans Hekland, member of the Board of Directors of LifeCare AS (the “Company”), has on 26 April 2024 sold 150,000 shares in the Company at an average price of NOK 3.05 per share. Following this transaction, Hannibal Invest AS holds 50,000 shares […]
Read more
April 26, 2024
Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intend to invest NOK 2 million and become the majority shareholder in RemovAid AS, a medical technology company based in Oslo, Norway. RemovAid is an ISO 13485 certified company who specializes in the […]
Read more